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Abstract
Background—The combination of calcineurin inhibitor (CNI) such as tacrolimus (TAC) or 
cyclosporine (CYSP) with methotrexate (MTX) or with mycophenolate mofetil (MMF) has been 
commonly used for Graft-versus-Host Disease (GVHD) prophylaxis after reduced intensity 
conditioning (RIC) allogeneic transplantation (alloHCT), but there are limited data comparing 
efficacy of the two regimens.
Methods—We evaluated 1564 adult patients who underwent RIC alloHCT for acute myeloid and 
lymphoid leukemia (AML/ALL), chronic myeloid leukemia (CML) and myelodysplastic 
syndrome (MDS) from 2000 to 2013 using HLA-identical sibling (MRD) or unrelated donor 
(URD) peripheral blood graft and received CYSP or TAC with MTX or MMF for GVHD 
prophylaxis. Primary outcomes of the study were acute and chronic GVHD and overall survival 
(OS). The study divided the patient population into four cohorts based on regimen: MMF-TAC, 
MMF-CYSP, MTX-TAC and MTX-CYSP.
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Results—In URD group, MMF-CYSP was associated with increased risk of grade II-IV acute 
GVHD (relative risk {RR} 1.78, P<0.001) and grade III-IV acute GVHD (RR 1.93, P=0.006) 
compared to MTX-TAC. In the URD group, use of MMF-TAC (versus MTX-TAC) lead to higher 
NRM. (HR 1.48, p=0.008). In either group, no there was no difference in chronic GVHD, disease-
free survival (DFS) and OS between the GVHD prophylaxis regimens.
Conclusion—For RIC alloHCT using MRD, there are no differences in outcomes based on 
GVHD prophylaxis. However, with URD RIC alloHCT, MMF-CYSP was inferior to MTX-based 
regimens for acute GVHD prevention, but all the regimens were equivalent in terms of chronic 
GVHD and OS. Prospective studies, targeting URD recipients are needed to confirm these results.
Keywords
calcineurin inhibitor; tacrolimus; cyclosporine; methotrexate; mycophenolate mofetil; Graft-
versus-Host Disease prophylaxis; reduced intensity conditioning; allogeneic hematopoietic cell 
transplantation
INTRODUCTION
Although the development of reduced intensity/non-myeloablative conditioning (RIC) has 
allowed patients who are ineligible for myeloablative conditioning (MAC) allogeneic 
hematopoietic cell transplantation (alloHCT) to have access to this potentially curative 
therapy, non-relapse mortality (NRM) remains a significant obstacle to its success1. The 
tight association between graft-versus-host disease (GVHD) and NRM has led to attempts to 
devise GVHD prevention strategies to decrease its incidence and severity2. For the past three 
decades, the regimen pioneered by the Seattle group combining a calcineurin inhibitor (CNI) 
with methotrexate (MTX) has been the most widely adopted for GVHD prevention3. 
Cyclosporine (CYSP) in combination with a short course of MTX has been widely used 
since the late 1980s4,5. In more recent years, tacrolimus (TAC) has emerged as an alternative 
to CYSP for GVHD prophylaxis6. CYSP and TAC share a final common pathway of 
inhibition of interleukin (IL)-2-mediated T cell expansion and cytotoxicity7. Randomized 
trials have shown that post-transplantation TAC-MTX is associated with decreased acute 
GVHD (aGVHD) compared with CYSP-MTX in patients with a matched sibling donor 
(MRD)8 or matched unrelated donor (URD) in the myeloablative setting9. There are, 
however, several caveats with the use of MTX, mainly delayed hematopoietic engraftment, 
increased oral mucositis and gastrointestinal toxicity as well as pulmonary and renal 
toxicity2,10-12. In patients undergoing RIC alloHCT, reducing procedure-related toxicities 
may be of critical importance, as these patients usually have greater comorbidities1. 
Therefore, in order to reduce MTX-associated toxicities, mycophenolate mofetil (MMF) has 
been investigated as a replacement for MTX in RIC regimens in recent years 13
Currently, at most transplant centers, GVHD prophylaxis is largely based on CNI (CYSP or 
TAC) in combination with short-course MTX or MMF14,15. There is, however, significant 
variability among centers in GVHD prophylaxis regimens used. In RIC alloHCT, MMF is 
widely used instead of MTX in combination with a calcineurin inhibitor for GVHD 
prophylaxis15, given the advantages of earlier engraftment and less mucositis. A recent 
Center for International Blood and Marrow Transplantation Research (CIBMTR) analysis16 
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demonstrated significantly worse overall survival (OS), NRM, and aGVHD and chronic 
GVHD (cGVHD) with MMF compared to MTX after RIC alloHCT from unrelated donors 
(URD). With the four regimens of MTX-CYSP, MMF-CYSP, MTX-TAC and MMF-TAC 
being used frequently as the current standard to prevent GVHD after RIC alloHCT, an 
important and unanswered question is whether one of them is superior to others in 
preventing GVHD. We aimed to describe and evaluate the comparative efficacy of the four 
commonly used regimens in a large cohort of patients using the CIBMTR database.
PATIENTS AND METHODS
Data Sources
The CIBMTR is a combined research program of the Medical College of Wisconsin and the 
National Marrow Donor Program, which consists of a voluntary network of more than 450 
transplantation centers worldwide that contribute detailed data on consecutive allogeneic and 
autologous transplantations to a centralized statistical center. Observational studies 
conducted by the CIBMTR are performed in compliance with all applicable federal 
regulations pertaining to the protection of human research participants. Protected health 
information issued in the performance of such research is collected and maintained in the 
CIBMTR’s capacity as a Public Health Authority under the Health Insurance Portability and 
Accountability Act Privacy Rule.
Patients
The study population included adult patients with acute myeloid leukemia (AML), acute 
lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML) and myelodysplastic 
syndrome (MDS) who underwent a first RIC alloHCT between 2000 and 2013 from an 
HLA-identical sibling or an 8/8- or 7/8-matched unrelated donor (HLA-A, -B, -C, -DRB1)17 
and received a combination of CNI (CYSP or TAC) and either MTX or MMF for 
prophylaxis against GVHD. Haploidentical related donor and cord blood transplants were 
excluded. All patients received a peripheral blood graft. Patients receiving ex vivo T cell 
depletion and bone marrow grafts were excluded given their small numbers.
Study Endpoints
The primary objective of the study was to evaluate and compare the risks of aGVHD, 
cGVHD and overall mortality with each of the four GVHD prophylaxis regimens in RIC 
alloHCT patients receiving PB graft. The primary endpoints of the study, therefore, were 
grade II-IV and III-IV aGVHD, cGVHD and OS. OS was defined as the time from alloHCT 
to death from any cause or until last follow up. Death from any cause was considered an 
event. Surviving patients were censored at last follow-up. Secondary endpoints included 
absolute neutrophil count (ANC) recovery, platelet recovery, DFS, relapse and NRM. 
Patients were censored at subsequent transplant or date of last follow up. DFS was defined 
as time from alloHCT to either relapse/progression or death from any cause. Patients alive 
were censored at the time of relapse/progression or last follow-up, whichever came first. 
NRM was defined as death from any cause in continuous remission and was summarized by 
cumulative incidence estimate with relapse as competing risk. Relapse was defined as 
molecular, cytogenetic, or morphologic evidence of disease recurrence. Relapse was 
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summarized by cumulative incidence estimate with NRM as the competing risk. For relapse 
and NRM, patients in continuous complete remission were censored at last follow-up. Acute 
GVHD and cGVHD were defined by the standard criteria18,19. For GVHD, death without 
the event was considered a competing risk. All patients received reduced intensity/non-
myeloablative conditioning (RIC) which was defined as total-body irradiation (TBI) ≤5 
Grays (single dose) or ≤8 Grays (fractionated), or busulfan ≤8 mg/kg (orally) or ≤6.4 mg/kg 
(intravenously) or melphalan less than 150 mg/m220.
Statistical Analysis
This is a retrospective cohort study describing and comparing outcomes after RIC alloHCT 
using MTX+CNI (TAC vs. CYSP) versus MMF+CNI (TAC vs. CYSP) as GVHD 
prophylaxis. To understand the impact of prophylaxis regimen on outcomes after alloHCT, 
the patient population was divided into four cohorts depending on CNI used and whether it 
was combined with MMF or MTX: MMF-TAC, MMF-CYSP, MTX-TAC and MTX-CYSP. 
Furthermore, two separate analyses were performed: one for the group with MRD and the 
other for the URD group.
The outcomes studied were acute (grade II-IV, grade III-IV) and chronic GVHD, OS, DFS, 
relapse, and NRM. Categorical variables were summarized as frequency counts and 
percentages and compared between GVHD prophylaxis cohorts using the Chi-Square test. 
Continuous variables were summarized as the median and range and compared using the 
Mann-Whitney test. Probabilities of OS and DFS were calculated using Kaplan-Meier 
estimator and compared between the cohorts using the log-rank test. Probabilities of NRM, 
relapse and cGVHD were calculated by cumulative incidence function accounting for 
competing risks. Comparisons of cumulative incidence across time cohorts were performed 
via Gray’s test. Multivariate Cox proportional hazards regression models for all the 
endpoints (aGVHD, cGVHD, OS, DFS, relapse, NRM, graft failure) were used to compare 
the treatment groups. The assumption of proportional hazards for each factor in the Cox 
model was tested using time-dependent covariates. There is no variable violating the 
proportional hazard assumption in this study. Stepwise selection was used to identify 
significant covariates that influenced outcomes to be included in the final model to get the 
adjusted treatment effects, the variables we considered in the variable selection included the 
patient-related [(age, sex, Karnofsky Performance Score (KPS), race, Hematopoietic Cell 
Transplantation-Comorbidity Index (HCT-CI)], disease-related (disease, disease status at 
alloHCT), donor-related [donor age (URD only), donor/recipient sex match and 
cytomegalovirus (CMV) match] and transplantation-related [year of transplant, in vivo T cell 
depletion using anti-thymocyte globulin (ATG) and use of TBI in the conditioning] 
variables. Statistical significance of the main effects was tested with level 0.01 accounting 
for multiple comparisons across the endpoints. Potential interactions between the main effect 
(GVHD prophylaxis) and significant adjusting were tested and there are no significant 
interactions at level of 0.01. Adjusted survival curves and cumulative incidence curves were 
generated stratified on the treatment groups and weighted averages of covariate values using 
the pooled sample proportion as the weight function. These adjusted curves represent 
likelihood of outcomes in populations with similar prognostic factors. The following power 
analyses were conducted for the main outcome grade II-IV aGVHD, given the current 
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patient and event number in each GVHD prophylaxis cohort of the two groups. For the 
MRD group, to detect a hazard ratio (HR) of 1.5 in one of the 6 pair-wise comparisons 
among treatments with significance level 0.05, the power ranges from 27% to 53% with 
Bonferroni adjustment used to adjust the multiple comparison problem. On the other hand, 
for the URD group, to detect a hazard ratio of 1.5 in one of the 6 pair-wise comparisons 
among treatments with significance level 0.05, the power ranges from 51% to 90%.
RESULTS
Patient, Disease, and Transplantation Characteristics
In the MRD group (n=690), patient, disease, and transplantation characteristics showed 
important differences (Table 1A). The median age at alloHCT was as low as 53 years in 
MTX-CYSP and as high as 61 years in MMF-TAC cohort (P<0.001). A significantly lower 
proportion of MTX-CYSP cohort patients had KPS of <90% (19%), whereas TAC-based 
cohorts had higher proportions of patients with KPS <90% (45-52%) (P<0.001). Of the four 
diseases included in the study, AML was the most common alloHCT indication (48-69%) in 
the MRD cohorts, followed by MDS (24-45%) (P<0.001). Donor/recipient CMV serostatus 
proportions were heterogeneous; for example, 11% of MTX-CYSP patients were donor/
recipient seronegative, compared to 19-25% in the other 3 cohorts (P<0.001). The 
combination of ATG with alkylator (busulfan [Bu], melphalan [Mel]), nucleoside analog 
(fludarabine; Flu), and/or TBI-based conditioning regimen was used in approximately a 
quarter of all four cohorts of MRD group. While in the 2000-2004 period, 43% of MTX-
CYSP and 50% of MMF-CYSP patients received alloHCT, in the most recent 2009-2013 
period, 17% and 29% of the respective CYSP cohorts had alloHCT. In contrast, 13% of 
MTX-TAC and 19% of MMF-TAC received alloHCT in 2000-2004, and in the 2009-2013 
period, 57% and 56% patients in the respective TAC cohorts underwent alloHCT (P<0.001). 
The median follow-up of survivors ranged from 48 to 59 months in the MRD cohorts.
In the URD group (n=874), pre-transplant variables were similar among the four cohorts, 
with some exceptions (Table 1B). AML (54-60%) and MDS (26-35%) were the two most 
common indications for alloHCT in the URD group (P=0.003). In the URD group, 70-85% 
patients in the four cohorts were fully-matched (8/8-) and 15-30% were matched at 7/8 loci 
with their donors (P=0.001). ATG was used in 41% of each of the two MMF cohorts, but at 
a higher frequency in the MTX cohorts (62% of MTX-CYSP and 54% of MTX-TAC 
cohorts) of the URD group (P<0.001). The median follow-up of survivors ranged from 49 to 
61 months in the URD cohorts. In the earliest period of 2000-2004, 17% and 18% of MTX-
CYSP and MMF-CYSP cohorts and 4% and 11% of MTX-TAC and MMF-TAC cohorts, 
respectively, received alloHCT (P<0.001). The proportions of alloHCT recipients in the most 
recent 2009-2014 were 28% and 38% in the CYSP cohorts and 58% and 43% in the TAC 
cohorts, respectively.
Acute GVHD
Univariate analysis demonstrated that in the MRD group, the cumulative incidences of grade 
II-IV aGVHD at day 100 post-transplant were 27% (95% CI 21-33%) in the MTX-CYSP 
cohort and 39% (95% CI 30-48%) in the MMF-CYSP cohort (Table 2A). In the MTX-TAC 
Chhabra et al. Page 6













and MMF-TAC cohorts of the MRD group, however, the incidences were 21% (95% CI 
17-26%) and 29% (95% CI 18-40%), respectively. Univariate analysis also showed that the 
cumulative incidences of grade III-IV aGVHD at day 100 were 8% (95% CI 5-12%), 18% 
(95% CI 12-26%), 8% (95% CI 5-11%) and 14% (95% CI 7-24%) in the MTX-CYSP, 
MMF-CYSP, MTX-TAC and MMF-TAC cohorts of MRD group, respectively (Table 2A). 
Multivariate analysis did not show any significant difference in the cumulative incidences of 
grade II-IV and grade III-IV aGVHD between the four cohorts in the MRD group (Table 3A, 
Figure 1A).
The URD cohorts had a higher cumulative incidence of grade II-IV acute GVHD on day 100 
post-alloHCT on univariate analysis: 32% (95%CI 22-45%) and 53% (95% CI 45-61%) in 
the MTX-CYSP and MMF-CYSP cohorts, respectively, and 37% (95% CI 32-41%) and 
47% (95% CI 41-54%) with using MTX-TAC and MMF-TAC, respectively (Table 2B). The 
cumulative incidences of grade III-IV aGVHD at day 100 were 15% (95% CI 8-25%), 21% 
(95% CI 15-28%), 13% (95% CI 10-17%) and 21% (95% CI 16-27%) in the MTX-CYSP, 
MMF-CYSP, MTX-TAC and MMF-TAC cohorts of URD group on univariate analysis, 
respectively (Table 2B). Multivariate analysis of the URD group demonstrated that MMF-
CYSP resulted in increased incidence of grade II-IV aGVHD compared to MTX-TAC (HR 
1.78, p<0.001) (Table 3B, Figure 1B) and MTX-CYSP (HR 2.23, p<0.001) (not shown in 
Table 3B). A significantly higher incidence of grade III-IV aGVHD was shown in the URD 
group with the GVHD prophylaxis of MMF-CYSP compared to MTX-TAC (HR 1.93, 
p=0.006) (Table 3B).
Chronic GVHD
The one-year cumulative incidences of cGVHD with MTX-CYSP, MMF-CYSP, MTX-TAC 
and MMF-TAC were 49% (95% CI 42-56%), 39% (95% CI 29-49%), 34% (95% CI 
29-40%) and 34% (95% CI 23-46%) on univariate analysis of the MRD group (Table 2A). 
Multivariate analysis did not reveal any significant difference in the incidence of cGVHD 
between the four cohorts in MRD group (Table 3A, Figure 2A). In this group, the addition of 
ATG to Flu/Bu conditioning was associated with lower cGVHD incidence (HR 0.55, 
p=0.001).
Univariate analysis demonstrated 1-year cumulative incidences of cGVHD with MTX-
CYSP, MMF-CYSP, MTX-TAC and MMF-TAC of 36% (95% CI 25-47%), 50% (95% CI 
42-58%), 40% (95% CI 35-45%) and 44% (95% CI 37-50%), respectively, in the URD 
group (Table 2B). There was no significant difference in the incidence of cGVHD between 
the four URD cohorts on multivariate analysis (Table 3B, Figure 2B).
Overall Survival
The MRD cohort exhibited 2-year OS of 59% (95% CI 52-66%) in the MTX-CYSP cohort, 
46% (95% CI 37-56%) in the MMF-CYSP cohort, 48% (95% CI 42-54%) in the MTX-TAC 
cohort and 47% (95% CI 35-59%) in the MMF-TAC cohort, on univariate analysis (Table 
2A). Multivariate analysis was unrevealing for a statistically significant difference between 
the four MRD cohorts (Table 3A, Figure 3A).
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The unadjusted probabilities of 2-year OS were 40% (95% CI 28-52%), 45% (95% CI 
37-53%), 47% (95% CI 42-51%) and 41% (95% CI 35-48%) in the MTX-CYSP, MMF-
CYSP, MTX-TAC and MMF-TAC cohorts of the URD group, respectively (Table 2B). 
Multivariate analysis did not show any significant difference among the cohorts of URD 
group (Table 3B, Figure 3B).
Disease-Free Survival
Univariate analysis demonstrated 2-year DFS of in the MRD group of 50% (95% CI 
43-57%) in the MTX-CYSP cohort, 41% (95% CI 32-50%) in the MMF-CYSP cohort, 41% 
(95% CI 36-47%) with MTX-TAC and 44% (95% CI 32-57%) with MMF-TAC (Table 2A). 
There was no significant difference in DFS between any of the GVHD cohorts in the MRD 
group on multivariate analysis (Table 3A).
In the URD group, DFS at 2 years was 36% (95% CI 25-48%) in the MTX-CYSP cohort, 
41% (95% CI 33-49%) in the MMF-CYSP cohort, 38% (95% CI 33-42%) in the MTX-TAC 
cohort and 33% (95% CI 27-40%) in the MMF-TAC cohort (Table 2B). Multivariate 
analysis did not show any significant difference in DFS among any of the URD cohorts 
(Table 3B).
Relapse
Univariate analysis revealed that in the MRD group, the cumulative incidences of relapse at 
2 years were 28% (95% CI 22-35%) and 36% (95% CI 27-46%) in the MTX-CYSP and 
MMF-CYSP cohorts, respectively, and 43% (95% CI 37-48%) and 33% (95% CI 22-46%) 
in the MTX-TAC and MMF-TAC cohorts, respectively (Table 2A). The risk of relapse was 
not shown to be significantly different among any of the four cohorts in the MRD group on 
multivariate analysis (Table 3A).
In the URD group, the 2-year cumulative incidences of relapse were 34% (95% CI 23-46%), 
27% (95% CI 21-35%), 40% (95% CI 35-44%) and 31% (95% CI 25-37%) in the MTX-
CYSP, MMF-CYSP, MTX-TAC and MMF-TAC cohorts, respectively, on univariate analysis 
(Table 2B). On multivariate analysis, URD patients receiving MMF-CYSP had a 
significantly lower risk of relapse, compared to those receiving MTX-TAC (HR 0.53, 
p<0.001) (Table 3B).
Non-relapse Mortality
On univariate analysis, the cumulative incidences of NRM at 2 years post-alloHCT in the 
MRD group were 21% (95% CI 16-27%), 23% (95% CI 15-32%), 16% (95% CI 12-21%), 
and 22% (95% CI 13-33%) in the MTX-CYSP, MMF-CYSP, MTX-TAC and MMF-TAC 
cohorts, respectively (Table 2A). Multivariate analysis did not show any significant 
difference in NRM among the four GVHD cohorts of MRD group (Table 3A).
The cumulative incidences of NRM at 2 years in the URD group were 31% (95% CI 
20-43%), 31% (95% CI 24-39%), 23% (95% CI 19-27%) and 37% (95% CI 31-43%) in the 
MTX-CYSP, MMF-CYSP, MTX-TAC and MMF-TAC cohorts, respectively (Table 2B). 
Multivariate analysis of the URD group demonstrated that compared to MTX-TAC, MMF-
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TAC was associated with increased risk of NRM (HR 1.48, p=0.008) (Table 3B), 
notwithstanding the faster neutrophil recovery observed with MMF-TAC compared with 
other regimens (P<0.001) (Table 2B).
DISCUSSION
The combinations of CNI with MTX or MMF for prevention of acute and chronic GVHD 
after alloHCT have been accepted as the current standard,6,8,9,18 although conflicting reports 
of outcomes with MMF- and MTX-containing CNI-based regimens have been noted. 
Despite the lack of prospective comparative data between MMF- and MTX-based regimens 
in RIC setting, MMF-CNI has been an established regimen after RIC alloHCT. While some 
studies have compared the CNIs (TAC vs. CYSP) and others have compared MTX- and 
MMF-containing GVHD prophylaxis, no study to date has investigated all four regimens 
concomitantly to compare the outcomes after RIC alloHCT and therefore, there has been no 
convincing evidence to date supporting the use of a particular regimen in the RIC setting.
We have made several important observations in this analysis. No single GVHD prevention 
regimen is superior, the limited power notwithstanding, to detect differences in aGVHD and 
survival outcomes in the MRD group. In those with URD, however, MTX-TAC performed 
better than MMF-CYSP and resulted in 44% risk reduction in grade II-IV and 48% risk 
reduction in grade III-IV aGVHD. Furthermore, MTX-CYSP resulted in 48% reduction in 
the incidence of grade II-IV aGVHD relative to MMF-CYSP but did not show statistically 
significant difference in the grade III-IV aGVHD risk. All four regimens resulted in similar 
cGVHD incidence after URD alloHCT. MTX-TAC, in addition, was associated with 32% 
lower NRM risk compared to MMF-TAC. Furthermore, MTX-TAC was associated with 
88% increase in relapse risk relative to MMF-CYSP but did not meet statistical significance 
when compared to MMF-TAC. Higher relapse risk observed with MTX-TAC did not 
translate into worse DFS and OS as the analysis revealed no significant difference between 
any of the cohorts in the URD group. No significant interaction was found between GVHD 
prophylaxis and the conditioning, but patients receiving Flu/Mel conditioning had 
significantly higher risk of grade II-IV (HR 1.75, P<0.001) and III-IV (HR 2.71, P<0.001) 
aGVHD compared to Flu/Bu regimen (Table 3B). The risks of cGVHD and NRM with 
Flu/Mel conditioning were also increased but did not meet statistical significance (P=0.03 
and 0.05, respectively).
Previously, three randomized studies had compared outcomes of alloHCT after CYSP21,22 
or TAC23 combined with MTX or MMF in the myeloablative setting. One study enrolled 
alloHCT from URD 21, another study from MRD22, and a third study included both23. None 
of the studies showed a statistically significant difference in the cumulative incidence of 
aGVHD between the regimens. Bolwell et al. reported the randomized study comparing 
MMF-CYSP and MTX-CYSP (n=40) after marrow transplantation using MRD22. No 
difference was observed in the incidence of GVHD or survival. Perkins et al. reported the 
results of a randomized phase II study comparing MMF-TAC and MTX-TAC after alloHCT 
from MRD and URD (n=89)23. Patients in the MMF cohort were less likely to experience 
severe mucositis, and the cumulative incidence of grade II-IV aGVHD was similar. 
However, the cumulative incidence of grade III-IV aGVHD was higher in the MMF arm 
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(19% vs. 4%, p=0.03), predominantly in MAC alloHCT using URD. A meta-analysis of the 
above-mentioned three randomized trials by the Cochrane Collaboration found no 
differences in the rates of aGVHD and cGVHD between the different regimens24. There was 
no evidence for a significant difference between MMF and MTX for the incidence of 
aGVHD and cGVHD, neutrophil engraftment, incidence of relapse, NRM and OS. The 
results are also in accord with those of a meta-analysis of 11 studies2 including 1076 
patients (a mix of MAC and RIC alloHCT recipients) that determined greater incidence of 
grade III-IV aGVHD in MMF recipients (HR 1.6; 95% CI 1.2-2.3). The increased risk of 
severe aGVHD with MMF was limited to the patients with URD and was not evident after 
MRD alloHCT. The three prospective trials had relatively small sample sizes and only 
included patients receiving MAC and therefore, their findings cannot be applied to RIC 
patients. It is noteworthy that none of the above-mentioned studies including the meta-
analyses demonstrated any significant differences in the relapse risk between MTX- and 
MMF-based GVHD regimens, unlike reported by our study. We can only speculate that there 
are unknown variables and confounders, in addition to the competing risk of low NRM that 
contributed to the increased relapse risk and neutralized any possible survival advantage 
MTX-based regimens could have had in URD group.
Eapen et al. compared outcomes between bone marrow and peripheral blood grafts for RIC 
alloHCT for patients with AML, MDS and non-Hodgkin lymphoma using URD in 88 US 
transplant centers (2000-2008) and reported no differences in outcomes between the two 
graft sources16, but patients receiving MMF (vs. MTX) had an increased risk of grade II-IV 
and III-IV aGVHD, cGVHD, NRM and worse OS. Patients with ALL and those receiving 
TBI were excluded in this study. Despite the differences in the primary objectives and 
patient populations between the two studies, the results of our analysis are in concordance 
with Eapen et al. study as we show MMF-containing regimens are associated with worse 
intermediate outcomes without impact on OS in the URD setting. This is an important study 
because it examines not only the efficacy of MTX or MMF, but also the added impact of 
TAC and CYSP in ensuring post-alloHCT outcomes. To compare only MTX and MMF 
would be assuming that the two CNIs, TAC and CYSP, have no difference in efficacy and 
can be used interchangeably and the study findings do not support this assumption.
Owing to the retrospective nature, the findings of the study need to be interpreted with 
caution. We acknowledge the differences in patient, disease, and transplant characteristics 
among the cohorts in both donor groups, especially the small sample size in certain cohorts 
(MMF-TAC cohort in the MRD group and MTX-CYSP in the URD group), differences in 
the proportions of ATG recipients in the cohorts of the URD group and the fact that the 
inclusion of ATG in the conditioning makes for a heterogeneous study population. These 
differences were addressed by performing a controlled analysis that accounted for all the 
characteristics and any center effects. We also examined the study population for differences 
in the outcomes of grade II-IV and III-IV aGVHD and cGVHD after excluding ATG 
recipients: univariate analysis showed cumulative incidence of grade II-IV aGVHD was 
highest with MMF-CYSP and lowest with MTX-TAC in both MRD and URD groups 
(Supplementary Tables 1A and 1B), but no significant differences in the incidence of grade 
III-IV aGVHD were observed in either group. Chronic GVHD was observed more 
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frequently with CYSP regimens than TAC in the MRD group, and similarly, in the URD 
group, MMF-CYSP had higher incidence of cGVHD compared to TAC-based regimens.
Despite carefully considering multiple potentially significant variables, the effect of 
unrecognized biases and residual confounding in the analysis cannot be ruled out. For 
instance, the dose of MTX and the dose and schedule of MMF in the regimens are variable 
among the transplant centers. Different dosing protocols for short-course MTX and different 
doses and duration of MMF adopted by the transplant centers were not captured in the 
database. It has been demonstrated that higher trough levels of MMF attributed to intensified 
dosing are correlated with a decreased incidence of severe GVHD after umbilical cord blood 
transplantation25,26. Moreover, the proportion of patients that did not receive all four doses 
of MTX due to severe oropharyngeal mucositis is not known. We cannot confirm that oral 
(and not intravenous) formulations of TAC and CYSP were used for all RIC alloHCT in the 
study. We also recognize the limitation in having variable therapeutic target blood level 
ranges for TAC and CYSP at different centers. Furthermore, we examined the cumulative 
incidences of cGVHD of any grade reported to the database and did not specifically evaluate 
the risk of moderate-to-severe or organ-specific cGVHD in the cohorts.
It is also important to note in the study the trade-off between low NRM and higher relapse 
risk with MTX-TAC compared to MMF-CYSP, resulting in no difference in OS. For this 
reason, it would be worth considering a future prospective study in the URD patient 
population using the composite endpoint such as GVHD- and relapse-free survival (GRFS) 
that assesses all significant and relevant endpoints27. The events for GRFS include grade III-
IV acute GVHD, systemic therapy-requiring chronic GVHD, relapse, or death. A similar 
composite end-point that has been in vogue is cGVHD- and relapse-free survival (CRFS), 
which includes survival without development of cGVHD, disease relapse or progression and 
death28. Interestingly, the analysis for both GRFS and CRFS did not reveal any significant 
differences among the MRD and URD cohorts (Table 2A and 2B).
In summary, in this observational study, we described the outcomes after RIC alloHCT using 
the four CNI-based regimens. This differentiates the study in that we considered the two 
drugs of each prophylactic regimen as a unique combination, which enabled comparisons 
among the four regimens. This analysis demonstrated equivalent outcomes in those with 
MRD using either of the four CNI-based combinations and inferior efficacy of MMF-based 
approach with regards to grade II-IV and III-IV aGVHD and NRM in those with URD. 
Moreover, the analysis did not suggest using a particular regimen in URD alloHCT 
recipients using RIC and peripheral blood graft, based on the lack of significant differences 
in OS, even though aGVHD risk was significantly improved with MTX-CNI regimens and 
there may be a trend for improved 1-year GRFS in the URD group with MTX-CNI than with 
MMF-CNI. Finally, a prospective randomized controlled trial of URD RIC alloHCT 
recipients is needed to evaluate these GVHD prophylaxis regimens with uniform dosing 
schedules and target pharmacokinetic ranges and using novel endpoints such as GRFS to 
confirm the findings of this study. The results of such a trial may also inform the ideal 
partner for GVHD prevention strategies such as post-transplant cyclophosphamide and other 
novel agents in the future clinical trials.
Chhabra et al. Page 11














Refer to Web version on PubMed Central for supplementary material.
REFERENCES:
1. Pinana JL, Valcarcel D, Fernandez-Aviles F, et al.: MTX or mycophenolate mofetil with CsA as 
GVHD prophylaxis after reduced-intensity conditioning PBSCT from HLA-identical siblings. Bone 
Marrow Transplant 45:1449–56, 2010 [PubMed: 20140024] 
2. Ram R, Yeshurun M, Vidal L, et al.: Mycophenolate mofetil vs. methotrexate for the prevention of 
graft-versus-host-disease--systematic review and meta-analysis. Leuk Res 38:352–60, 2014 
[PubMed: 24418750] 
3. Alyea EP: Graft-Versus-Host Disease Prevention: Corticosteroids Revisited. J Clin Oncol 34:1836–
7, 2016 [PubMed: 27091715] 
4. Storb R, Deeg HJ, Pepe M, et al.: Methotrexate and cyclosporine versus cyclosporine alone for 
prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for 
leukemia: long-term follow-up of a controlled trial. Blood 73:1729–34, 1989 [PubMed: 2653461] 
5. Storb R, Deeg HJ, Whitehead J, et al.: Methotrexate and cyclosporine compared with cyclosporine 
alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N 
Engl J Med 314:729–35, 1986 [PubMed: 3513012] 
6. Nieto Y, Patton N, Hawkins T, et al.: Tacrolimus and mycophenolate mofetil after nonmyeloablative 
matched-sibling donor allogeneic stem-cell transplantations conditioned with fludarabine and low-
dose total body irradiation. Biol Blood Marrow Transplant 12:217–25, 2006 [PubMed: 16443519] 
7. Storb R, Antin JH, Cutler C: Should methotrexate plus calcineurin inhibitors be considered standard 
of care for prophylaxis of acute graft-versus-host disease? Biol Blood Marrow Transplant 16:S18–
27, 2010 [PubMed: 19857584] 
8. Ratanatharathorn V, Nash RA, Przepiorka D, et al.: Phase III study comparing methotrexate and 
tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease 
prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 92:2303–14, 1998 
[PubMed: 9746768] 
9. Nash RA, Antin JH, Karanes C, et al.: Phase 3 study comparing methotrexate and tacrolimus with 
methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow 
transplantation from unrelated donors. Blood 96:2062–8, 2000 [PubMed: 10979948] 
10. Neumann F, Graef T, Tapprich C, et al.: Cyclosporine A and mycophenolate mofetil vs 
cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell 
transplantation from HLA-identical siblings. Bone Marrow Transplant 35:1089–93, 2005 
[PubMed: 15821769] 
11. Cutler C, Li S, Kim HT, et al.: Mucositis after allogeneic hematopoietic stem cell transplantation: a 
cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease 
prophylaxis regimens. Biol Blood Marrow Transplant 11:383–8, 2005 [PubMed: 15846292] 
12. Ho VT, Weller E, Lee SJ, et al.: Prognostic factors for early severe pulmonary complications after 
hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 7:223–9, 2001 [PubMed: 
11349809] 
13. McSweeney PA, Niederwieser D, Shizuru JA, et al.: Hematopoietic cell transplantation in older 
patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-
tumor effects. Blood 97:3390–400, 2001 [PubMed: 11369628] 
14. Ostronoff F, Ostronoff M, Souto-Maior AP, et al.: Prospective trial of mycophenolate mofetil-
cyclosporine A prophylaxis for acute GVHD after G-CSF stimulated allogeneic bone marrow 
transplantation with HLA-identical sibling donors in patients with severe aplastic anemia and 
hematological malignancies. Clin Transplant 23:33–8, 2009
15. Ruutu T, van Biezen A, Hertenstein B, et al.: Prophylaxis and treatment of GVHD after allogeneic 
haematopoietic SCT: a survey of centre strategies by the European Group for Blood and Marrow 
Transplantation. Bone Marrow Transplant 47:1459–64, 2012 [PubMed: 22410750] 
Chhabra et al. Page 12













16. Eapen M, Logan BR, Horowitz MM, et al.: Bone marrow or peripheral blood for reduced-intensity 
conditioning unrelated donor transplantation. J Clin Oncol 33:364–9, 2015 [PubMed: 25534391] 
17. Weisdorf D, Spellman S, Haagenson M, et al.: Classification of HLA-matching for retrospective 
analysis of unrelated donor transplantation: revised definitions to predict survival. Biol Blood 
Marrow Transplant 14:748–58, 2008 [PubMed: 18541193] 
18. Przepiorka D, Weisdorf D, Martin P, et al.: 1994 Consensus Conference on Acute GVHD Grading. 
Bone Marrow Transplant 15:825–8, 1995 [PubMed: 7581076] 
19. Filipovich AH, Weisdorf D, Pavletic S, et al.: National Institutes of Health consensus development 
project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging 
working group report. Biol Blood Marrow Transplant 11:945–56, 2005 [PubMed: 16338616] 
20. Bacigalupo A, Ballen K, Rizzo D, et al.: Defining the intensity of conditioning regimens: working 
definitions. Biol Blood Marrow Transplant 15:1628–33, 2009 [PubMed: 19896087] 
21. Kiehl MG, Schafer-Eckart K, Kroger M, et al.: Mycophenolate mofetil for the prophylaxis of acute 
graft-versus-host disease in stem cell transplant recipients. Transplant Proc 34:2922–4, 2002 
[PubMed: 12431658] 
22. Bolwell B, Sobecks R, Pohlman B, et al.: A prospective randomized trial comparing cyclosporine 
and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD 
prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant 
34:621–5, 2004 [PubMed: 15300236] 
23. Perkins J, Field T, Kim J, et al.: A randomized phase II trial comparing tacrolimus and 
mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease 
prophylaxis. Biol Blood Marrow Transplant 16:937–47, 2010 [PubMed: 20102746] 
24. Kharfan-Dabaja M, Mhaskar R, Reljic T, et al.: Mycophenolate mofetil versus methotrexate for 
prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell 
transplantation. Cochrane Database Syst Rev:CD010280, 2014
25. Bejanyan N, Rogosheske J, DeFor T, et al.: Higher Dose of Mycophenolate Mofetil Reduces Acute 
Graft-versus-Host Disease in Reduced-Intensity Conditioning Double Umbilical Cord Blood 
Transplantation. Biol Blood Marrow Transplant 21:926–33, 2015 [PubMed: 25655791] 
26. Harnicar S, Ponce DM, Hilden P, et al.: Intensified Mycophenolate Mofetil Dosing and Higher 
Mycophenolic Acid Trough Levels Reduce Severe Acute Graft-versus-Host Disease after Double-
Unit Cord Blood Transplantation. Biol Blood Marrow Transplant 21:920–5, 2015 [PubMed: 
25687796] 
27. Holtan SG, DeFor TE, Lazaryan A, et al.: Composite end point of graft-versus-host disease-free, 
relapse-free survival after allogeneic hematopoietic cell transplantation. Blood 125:1333–8, 2015 
[PubMed: 25593335] 
28. Pasquini MC, Logan B, Jones RJ, et al.: Blood and Marrow Transplant Clinical Trials Network 
Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-
versus-Host Disease Prevention Trials. Biol Blood Marrow Transplant 24:1274–1280, 2018 
[PubMed: 29325830] 
Chhabra et al. Page 13














There is lack of comparative efficacy analysis between mycophenolate-calcineurin 
inhibitor (CNI) and methotrexate-CNI regimens for Graft-Versus-Host Disease (GVHD) 
prophylaxis in the setting of reduced intensity conditioning (RIC) allogeneic 
transplantation.
In this retrospective cohort study evaluating the efficacy of the four commonly used CNI-
based regimens in a large cohort of patients, mycophenolate-based approach showed a 
higher risk for acute GVHD and non-relapse mortality in RIC allogeneic transplant 
recipients with unrelated donor. Nonetheless, lack of overall survival advantage suggests 
that no GVHD prophylaxis regimen is superior.
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A. Adjusted curves for cumulative incidence of Grade II-IV acute GVHD in matched sibling 
donor recipients of reduced intensity conditioning (RIC) allogeneic transplants (alloHCT) 
using one of the four GVHD prophylaxis regimens: tacrolimus (TAC)-methotrexate (MTX), 
cyclosporine (CYSP)-MTX, CYSP-mycophenolate mofetil (MMF), and TAC-MMF.
B. Adjusted curves for cumulative incidence of Grade II-IV acute GVHD in matched 
unrelated donor RIC alloHCT patients on one of the four GVHD prophylaxis regimens: 
TAC-MTX, CYSP-MTX, CYSP-MMF, and TAC-MMF.
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A. Adjusted curves for cumulative incidence of chronic GVHD in matched sibling donor 
RIC alloHCT patients on one of the four GVHD prophylaxis regimens: TAC-MTX, CYSP-
MTX, CYSP-MMF, and TAC-MMF.
B. Adjusted curves for cumulative incidence of chronic GVHD in matched unrelated donor 
RIC alloHCT patients receiving one of the four GVHD prophylaxis regimens: TAC-MTX, 
CYSP-MTX, CYSP-MMF, and TAC-MMF.
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A. Adjusted curves for overall survival in matched sibling donor RIC alloHCT patients 
receiving one of the four GVHD prophylaxis regimens: TAC-MTX, CYSP-MTX, CYSP-
MMF, and TAC-MMF.
B. Adjusted curves for overall survival in matched unrelated donor RIC alloHCT patients 
receiving one of the four GVHD prophylaxis regimens: TAC-MTX, CYSP-MTX, CYSP-
MMF, TAC-MMF.
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Table 1A.
Characteristics of adult patients receiving their first reduced intensity conditioning allogeneic transplant for 
AML, ALL, CML, MDS with a peripheral blood stem cell graft from a matched related donor and treated with 










Number of patients 220 110 296 64
Number of centers 49 30 58 23
Patient-related
Age at transplant, years, median (range) 53 (20-71) 58 (20-76) 60 (19-77) 61 (19-73) <0.001
Age at transplant, years <0.001
18-29 10 (5) 3 (3) 5 (2) 4 (6)
30-39 34 (15) 4 (4) 14 (5) 3 (5)
40-49 42 (19) 13 (12) 26 (9) 3 (5)
50-64 108 (49) 59 (54) 184 (62) 37 (58)
65+ 26 (12) 31 (28) 67 (23) 17 (27)
Race <0.001
Caucasian 120 (54) 94 (85) 264 (89) 57 (89)
Non-Caucasian 72 (33) 9 (8) 26 (9) 7 (11)
Sorror comorbidity index <0.001
Prior to 2007 170 (77) 68 (61) 93 (31) 21 (33)
0-1 25 (11) 17 (15) 87 (29) 10 (16)
2+ 20 (9) 24 (22) 113 (38) 33 (52)
KPS <0.001
<90 43 (19) 40 (36) 154 (52) 29 (45)
≧90 171 (78) 69 (63) 138 (47) 35 (55)
Disease-related
Disease <0.001
AML 111 (50) 55 (50) 203 (69) 31 (48)
ALL 15 (6) 10 (9) 8 (3) 3 (5)
CML 43 (20) 8 (7) 11 (4) 1 (2)
MDS 52 (24) 37 (34) 74 (25) 29 (45)
Disease status at transplant *** <0.001
Early 109 (50) 62 (56) 189 (64) 37 (58)
Intermediate 64 (29) 14 (13) 40 (14) 8 (13)
Advanced 44 (20) 29 (26) 57 (19) 17 (27)
Donor-related
Donor-recipient gender match 0.11
M/M 70 (32) 35 (32) 92 (31) 28 (44)
M/F 64 (29) 25 (22) 59 (20) 10 (16)
F/M 42 (19) 28 (25) 85 (29) 15 (23)
F/F 44 (20) 23 (21) 60 (20) 11 (17)
Donor-recipient CMV status <0.001























+/+ 138 (63) 42 (38) 124 (42) 30 (47)
+/− 25 (11) 13 (12) 30 (10) 5 (8)
−/+ 27 (12) 27 (25) 78 (26) 15 (23)
−/− 24 (11) 28 (25) 56 (19) 14 (22)
Transplant-related
Conditioning regimen & ATG <0.001
Bu + Flu ± others 69 (31) 18 (16) 149 (50) 18 (28)
Flu + Mel ± others 72 (33) 36 (33) 69 (23) 18 (28)
TBI ± Cy ± Flu ± others 26 (12) 30 (27) 17 (6) 12 (19)
ATG ± Bu ± Flu ± others 50 (23) 11 (10) 60 (20) 15 (23)
ATG ± TBI ± others 3 (1) 15 (14) 1 (<1) 1 (2)
Year of transplant <0.001
2000-2004 110 (50) 47 (43) 39 (13) 12 (19)
2005-2008 73 (33) 31 (28) 88 (30) 16 (25)
2009-2013 37 (17) 32 (29) 169 (57) 36 (56)
Follow-up of survivors, months, median (range) 54 (2-138) 59 (3-166) 56 (3-154) 48 (23-124)
Abbreviations: AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myeloid leukemia; MDS, myelodysplastic 
syndrome; TAC, tacrolimus; CYSP, cyclosporine; MTX, methotrexate; MMF, mycophenolate mofetil; ATG, anti-thymocyte globulin; KPS, 
Karnofsky Performance Score; M, male; F, female; CMV, cytomegalovirus; Bu, busulfan; Flu, fludarabine; Mel, melphalan; Cy, cyclophosphamide; 
TBI, total body irradiation
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Table 1B.
Characteristics of adult patients receiving their first reduced intensity transplant from an unrelated donor for 
AML, ALL, CML, MDS from an unrelated donor with a peripheral blood stem cell graft and treated with CNI 










Number of patients 71 153 432 218
Number of centers 26 35 68 39
Patient-related
Age at transplant, years
Median (range) 59 (23-74) 62 (21-76) 61 (18-76) 60 (20-79) 0.08
Age at transplant, years 0.16
18-29 3 (4) 9 (6) 18 (4) 8 (3)
30-39 4 (6) 7 (5) 23 (5) 20 (9)
40-49 9 (13) 12 (8) 36 (8) 23 (11)
50-64 40 (56) 67 (44) 226 (52) 113 (52)
65+ 15 (21) 58 (38) 131 (30) 54 (25)
Race < 0.001
Caucasian 60 (85) 138 (90) 410 (95) 204 (93)
Non-Caucasian 6 (8) 10 (7) 21 (5) 12 (6)
Missing 5 (7) 5 (3) 1 (<1) 2 (<1)
Sorror co-morbidity index < 0.001
Prior to 2007 46 (65) 75 (49) 129 (30) 98 (45)
0-1 14 (20) 29 (19) 108 (25) 40 (18)
2+ 10 (14) 42 (27) 188 (43) 75 (34)
Missing 1 (1) 7 (5) 7 (2) 5 (2)
Karnofsky performance score at transplant 0.07
<90 20 (28) 56 (37) 196 (45) 100 (46)
≧90 47 (66) 93 (61) 223 (52) 112 (51)
Missing 5 (6) 4 (3) 13 (3) 6 (3)
Disease-related
Disease 0.003
AML 39 (55) 92 (60) 248 (57) 120 (55)
ALL 3 (4) 12 (8) 9 (2) 15 (7)
CML 9 (13) 9 (6) 23 (6) 7 (3)
MDS 20 (28) 40 (26) 152 (35) 76 (35)
Disease status at transplant **** 0.39
Early 40 (56) 95 (62) 255 (59) 125 (57)
Intermediate 9 (13) 16 (10) 71 (16) 33 (14)
Advanced 19 (26) 40 (26) 97 (22) 52 (24)
Missing 3 (4) 2 (1) 9 (2) 10 (5)
Donor-related
Donor type 0.001























Unrelated, 8/8-matched 50 (70) 120 (78) 369 (85) 163 (75)
Unrelated, 7/8-matched 21 (30) 33 (22) 63 (15) 55 (25)
Unrelated donor age at transplant, years
Median (range) 33 (20-60) 32 (20-56) 31 (18-61) 33 (18-60) 0.25
Unrelated donor age at transplant, years 0.27
18-29 34 (49) 75 (49) 235 (54) 106 (49)
30-49 25 (35) 66 (43) 152 (35) 94 (43)
50-60 6 (8) 8 (5) 27 (6) 9 (4)
Missing 6 (8) 4 (3) 18 (4) 9 (4)
Donor-recipient gender match 0.06
M/M 25 (35) 56 (37) 201 (47) 83 (38)
M/F 25 (35) 39 (25) 121 (28) 58 (27)
F/M 9 (13) 32 (21) 54 (13) 35 (16)
F/F 12 (17) 26 (17) 56 (13) 42 (19)
Donor-recipient CMV status 0.82
+/+ 12 (17) 42 (27) 102 (24) 50 (23)
+/− 6 (8) 16 (10) 43 (10) 16 (7)
−/+ 30 (42) 52 (34) 175 (41) 89 (41)
−/− 22 (31) 38 (25) 101 (23) 57 (26)
Missing 1 (1) 5 (3) 12 (3) 6 (3)
Transplant-related
Conditioning regimen &ATG < 0.001
Bu + Flu ± others 11 (15) 13 (9) 121 (28) 30 (14)
Flu + Mel ± others 13 (18) 20 (13) 67 (16) 48 (22)
TBI ± Cy ± Flu ± others 3 (4) 57 (37) 9 (2) 49 (22)
ATG ± Bu ± Flu ± others 41 (58) 52 (34) 235 (54) 88 (40)
ATG ± TBI ± others 3 (4) 11 (7) 0 (0) 3 (1)
Year of transplant < 0.001
2000-2004 12 (17) 28 (18) 17 (4) 24 (11)
2005-2008 39 (55) 67 (44) 164 (38) 100 (46)
2009-2013 20 (28) 58 (38) 251 (58) 94 (43)
Follow-up of survivors, months, median (range) 60 (4-120) 71 (16-191) 48 (5-126) 61 (12-146)
Abbreviations: AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myeloid leukemia; MDS, myelodysplastic 
syndrome; TAC, tacrolimus; CYSP, cyclosporine; MTX, methotrexate; MMF, mycophenolate mofetil; ATG, anti-thymocyte globulin; KPS, 
Karnofsky Performance Score; M, male; F, female; CMV, cytomegalovirus; Bu, busulfan; Flu, fludarabine; Mel, melphalan; Cy, cyclophosphamide; 
TBI, total body irradiation
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Table 2A.









Outcomes Prob, % (95% CI) Prob, % (95% CI) Prob, % (95% CI) Prob, % (95% CI) P-value
aGVHD II-IV
    1 months 14 (9-19) 20 (13-28) 7 (4-10) 21 (12-32) <0.001
    2 months 21 (15-26) 33 (25-42) 15 (11-20) 24 (14-35) 0.003
    100-day 27 (21-33) 39 (30-48) 21 (17-26) 29 (18-40) 0.01
aGVHD III-IV
    1 months 2 (1-5) 11 (6-18) 2 (1-4) 14 (7-24) 0.02
    2 months 6 (3-9) 16 (9-23) 6 (4-9) 14 (7-24) 0.03
    100-day 8 (5-12) 18 (12-26) 8 (5-11) 14 (7-24) 0.04
cGVHD
    100-day 6 (3-10) 3 (1-7) 2 (1-4) 3 (0-9) 0.24
    6 months 30 (24-37) 26 (18-35) 18 (13-22) 18 (9-28) 0.01
    1-year 49 (42-56) 39 (29-49) 34 (29-40) 34 (23-46) 0.01
Overall Survival
    100-day 91 (87-94) 87 (80-93) 93 (90-96) 83 (73-91) 0.08
    6 months 80 (75-85) 75 (67-83) 78 (73-83) 69 (57-79) 0.31
    1-year 67 (61-74) 57 (48-66) 60 (54-66) 55 (42-67) 0.13
    2-year 59 (52-66) 46 (37-56) 48 (42-54) 47 (35-59) 0.05
DFS
    100-day 82 (76-87) 76 (67-83) 76 (71-81) 71 (60-82) 0.22
    6 months 68 (61-74) 61 (51-70) 61 (55-66) 54 (42-66) 0.17
    1-year 57 (50-64) 46 (37-56) 50 (45-56) 48 (35-60) 0.22
    2-year 50 (43-57) 41 (32-50) 41 (36-47) 44 (32-57) 0.21
Relapse
    100-day 10 (6-14) 17 (10-24) 21 (16-25) 14 (7-24) 0.005
    6 months 18 (13-23) 26 (18-35) 32 (27-38) 32 (21-44) <0.001
    1-year 24 (19-30) 34 (25-43) 37 (31-43) 33 (22-46) 0.007
    2-year 28 (22-35) 36 (27-46) 43 (37-48) 33 (22-46) 0.01
NRM
    100-day 9 (5-13) 7 (3-13) 3 (2-6) 14 (7-24) 0.04
    6 months 15 (10-20) 13 (7-20) 7 (4-10) 14 (7-24) 0.02
    1-year 19 (14-24) 20 (13-28) 13 (9-17) 19 (10-30) 0.15
    2-year 21 (16-27) 23 (15-32) 16 (12-21) 22 (13-33) 0.29
GRFS
    100-day 71 (64-77) 61 (52-70) 69 (63-74) 64 (52-75) 0.36
    6 months 39 (32-46) 35 (26-44) 42 (37-48) 39 (27-51) 0.53
    1-year 16 (11-22) 16 (9-24) 22 (18-27) 23 (13-34) 0.23
    2-year 13 (9-18) 13 (7-20) 15 (11-19) 13 (6-22) 0.94























    100-day 79 (73-84) 75 (67-83) 74 (69-79) 70 (59-81) 0.49
    6 months 56 (49-62) 49 (39-58) 53 (47-58) 50 (37-62) 0.67
    1-year 40 (33-47) 30 (22-40) 39 (34-45) 40 (28-52) 0.35
    2-year 35 (29-42) 27 (19-36) 31 (25-36) 34 (23-46) 0.52
Neutrophil recovery
    14 days 36 (30-43) 38 (29-47) 35 (30-41) 57 (45-69) 0.02
    28 days 93 (89-96) 91 (84-96) 96 (94-98) 98 (92-100) 0.07
Platelet recovery
    14 days 14 (9-19) 29 (20-39) 20 (15-25) 22 (13-34) 0.02
    28 days 78 (71-83) 84 (75-91) 82 (77-87) 93 (85-98) 0.01
Abbreviations: TAC, tacrolimus; CYSP, cyclosporine; MTX, methotrexate; MMF, mycophenolate mofetil; Prob, probability; N, number; CI, 
confidence interval; aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; NRM, non-relapse mortality; DFS, 
disease-free survival; GRFS, GVHD- and relapse-free survival; CRFS, chronic GVHD- and relapse-free survival.
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Table 2B.



















    1 months 15 (8-25) 38 (30-45) 18 (15-22) 26 (21-32) <0.001
    2 months 31 (21-42) 51 (43-59) 33 (29-37) 41 (35-48) <0.001
    100-day 32 (22-44) 53 (45-61) 37 (32-41) 47 (41-54) <0.001
aGVHD III-IV
    1 months 8 (3-16) 16 (10-22) 8 (6-11) 14 (10-19) 0.03
    2 months 15 (8-25) 21 (15-28) 12 (9-16) 19 (14-25) 0.02
    100-day 15 (8-25) 21 (15-28) 13 (10-17) 21 (16-27) 0.06
cGVHD
    100-day 3 (0-8) 10 (6-15) 4 (3-6) 2 (1-5) 0.03
    6 months 19 (10-29) 36 (28-43) 22 (18-26) 26 (21-33) 0.01
    1-year 36 (25-47) 50 (42-58) 40 (35-45) 44 (37-50) 0.11
Overall Survival
    100-day 77 (67-86) 83 (77-89) 87 (83-90) 81 (75-86) 0.12
    6 months 66 (54-76) 69 (62-76) 78 (74-82) 67 (61-73) 0.006
    1-year 54 (42-66) 57 (49-65) 60 (55-65) 49 (42-56) 0.06
    2-year 40 (28-52) 45 (37-53) 47 (42-51) 41 (35-48) 0.49
DFS
    100-day 72 (60-82) 73 (66-80) 74 (69-78) 70 (64-76) 0.78
    6 months 59 (47-71) 60 (52-68) 61 (57-66) 56 (49-62) 0.59
    1-year 50 (38-62) 50 (42-58) 48 (43-53) 41 (34-47) 0.21
    2-year 36 (25-48) 41 (33-49) 38 (33-42) 33 (27-40) 0.47
Relapse
    100-day 16 (9-26) 15 (10-21) 17 (14-21) 15 (11-20) 0.85
    6 months 26 (16-37) 19 (13-26) 26 (22-31) 24 (18-30) 0.29
    1-year 30 (20-42) 23 (17-30) 35 (30-39) 28 (22-34) 0.03
    2-year 34 (23-46) 27 (21-35) 40 (35-44) 31 (25-37) 0.02
NRM
    100-day 12 (5-21) 12 (7-17) 9 (6-12) 15 (10-20) 0.16
    6 months 15 (7-25) 21 (15-28) 13 (10-16) 21 (16-27) 0.02
    1-year 20 (11-30) 27 (20-34) 17 (14-21) 31 (25-37) <0.001
    2-year 30 (19-42) 31 (24-39) 23 (19-27) 36 (29-42) 0.005
GRFS
    100-day 63 (52-74) 52 (44-60) 63 (58-67) 58 (51-65) 0.12
    6 months 41 (30-52) 31 (24-38) 38 (34-43) 33 (26-39) 0.20
    1-year 24 (15-34) 14 (9-21) 16 (13-20) 11 (8-16) 0.10
    2-year 13 (6-22) 10 (5-15) 11 (8-14) 7 (4-11) 0.29























    100-day 66 (55-77) 67 (60-75) 73 (68-77) 70 (63-76) 0.52
    6 months 49 (37-61) 47 (40-55) 55 (50-59) 47 (41-54) 0.22
    1-year 37 (27-49) 35 (27-42) 37 (32-42) 31 (25-38) 0.50
    2-year 21 (12-32) 26 (20-34) 28 (24-33) 22 (17-28) 0.31
Neutrophil recovery
    14 days 46 (35-58) 32 (25-40) 35 (31-40) 69 (62-75) <0.001
    28 days 97 (92-100) 96 (92-99) 96 (94-98) 95 (92-98) 0.91
Platelet recovery
    14 days 17 (9-27) 19 (13-27) 19 (13-27) 18 (13-24) 0.61
    28 days 73 (62-84) 82 (75-89) 83 (79-87) 80 (74-85) 0.38
Abbreviations: TAC, tacrolimus; CYSP, cyclosporine; MTX, methotrexate; MMF, mycophenolate mofetil; Prob, probability; N, number; CI, 
confidence interval; aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; NRM, non-relapse mortality; DFS, 
disease-free survival; GRFS, GVHD- and relapse-free survival; CRFS, chronic GVHD- and relapse-free survival.
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Table 3A.
Multivariate analyses in related donor RIC alloHCT
N (%) Est (95% CI) P-value
Grade II-IV Acute GVHD
GVHD prophylaxis 0.14
MTX-TAC (reference) 290 (43%) 1.0
MMF-CYSP 109 (16%) 1.6 (1.1, 2.4) 0.02
MTX-CYSP 213 (32%) 1.3 (0.9, 1.8) 0.17
MMF-TAC 63 (9%) 1.2 (0.7, 2.0) 0.44
Conditioning regimen / ATG <0.001
BU+FLU+/−others (reference) 248 (37%) 1.00
ATG+/−BU+/−FLU+/−others 134 (20%) 0.9 (0.4, 1.1) 0.10
FLU+LPAM+/−others 193 (29%) 1.7 (1.2, 2.4) 0.001
TBI+/−CY+/−FLU+/−others 100 (15%) 1.2 (0.8, 1.9) 0.31
Karnofsky performance score 0.04
<90 (reference) 258 (38%) 1.0
90-100 404 (60%) 0.7 (0.5, 0.9) 0.01
Missing 13 (2%) 0.8 (0.2, 2.5) 0.69
Grade III-IV aGVHD
GVHD prophylaxis 0.26
MTX-TAC (reference) 291 (43%) 1.0
MMF-CYSP 109 (16%) 1.6 (0.9, 2.8) 0.15
MTX-CYSP 213 (31%) 0.9 (0.5, 1.6) 0.76
MMF-TAC 63 (9%) 1.5 (0.8, 3.1) 0.23
Conditioning regimen / ATG 0.03
Bu+Flu+/−others (reference) 248 (37%) 1.0
ATG+/−Bu+/−Flu+/−others 134 (20%) 0.6 (0.3, 1.3) 0.25
Flu+Mel+/−others 193 (29%) 1.7 (1.0, 2.8) 0.04




MTX-TAC (reference) 287 (43%) 1.0
MMF-CYSP 103 (15%) 1.1 (0.7, 1.7) 0.58
MTX-CYSP 210 (32%) 1.3 (0.9, 1.8) 0.13
MMF-TAC 63 (9%) 1.3 (0.8, 2.0) 0.25
Conditioning regimen / ATG 0.006
Bu+Flu+/−others (reference) 246 (37%) 1.0
ATG+/−Bu+/−Flu+/−others 134 (20%) 0.5 (0.4, 0.8) 0.001
Flu+Mel+/−others 186 (28%) 1.0 (0.7, 1.4) 0.95
TBI+/−Cy+/−Flu+/−others 97 (15%) 1.1 (0.7, 1.7) 0.66
Disease status 0.04
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N (%) Est (95% CI) P-value
Early (reference) 385 (58%) 1.0
Advanced 142 (21%) 1.1 (0.8, 1.4) 0.74
Intermediate 117 (18%) 1.2 (0.8, 1.6) 0.37
Missing 19 (3%) 2.5 (1.3, 4.7) 0.005
Donor-recipient CMV match 0.02
−/− (reference) 113 (17%) 1.0
+/+ 321 (48%) 1.1 (0.7, 1.5) 0.74
+/− 71 (11%) 0.6 (0.4, 1.0) 0.05
−/+ 144 (22%) 0.7 (0.5, 1.1) 0.11
Missing 14 (2%) 1.8 (0.7, 4.5) 0.22
Donor-recipient sex match 0.01
M-M (reference) 219 (33%) 1.0
F-F 131 (20%) 1.4 (1.0, 2.0) 0.06
F-M 161 (24%) 1.7 (1.2, 2.4) 0.002
M-F 152 (23%) 1.5 (1.1, 2.0) 0.02
Race 0.005
Caucasian (reference) 512 (77%) 1.0
Missing 43 (6%) 0.9 (0.5, 1.6) 0.78




MTX-TAC (reference) 296 (43%) 1.0
MMF-CYSP 110 (16%) 1.2 (0.9, 1.5) 0.26
MTX-CYSP 220 (32%) 1.0 (0.8, 1.3) 0.77
MMF-TAC 64 (9%) 1.1 (0.8, 1.6) 0.52
Age at transplant, years 0.002
18-29 (reference) 22 (3%) 1.0
30-39 55 (8%) 1.6 (0.6, 4.0) 0.35
40-49 84 (12%) 1.9 (0.8, 4.7) 0.13
50-64 388 (56%) 2.8 (1.2, 6.4) 0.01
65+ 141 (20%) 3.3 (1.4, 7.7) 0.006
Disease 0.008
AML (reference) 400 (58%) 1.0
ALL 35 (5%) 1.3 (0.8, 2.0) 0.28
CML 63 (9%) 0.6 (0.3, 1.0) 0.05
MDS 192 (28%) 0.7 (0.6, 0.9) 0.02
Disease status 0.01
Early (reference) 397 (57%) 1.0
Advanced 147 (21%) 1.4 (1.1, 1.8) 0.004
Intermediate 126 (18%) 0.89 (0.6, 1.2) 0.50
Missing 20 (3%) 1.51 (0.8, 2.7) 0.16
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N (%) Est (95% CI) P-value
Karnofsky performance score 0.006
<90 (reference) 264 (38%) 1.0
90-100 413 (60%) 0.7 (0.6, 0.8) 0.002




MTX-TAC (reference) 287 (43%) 1.0
MMF-CYSP 108 (16%) 1.1 (0.9, 1.5) 0.29
MTX-CYSP 212 (32%) 0.8 (0.7, 1.1) 0.19
MMF-TAC 63 (9%) 1.1 (0.8, 1.5) 0.71
Disease status 0.003
Early (reference) 390 (58%) 1.0
Advanced 146 (22%) 1.4 (1.1, 1.8) 0.002
Intermediate 116 (17%) 0.9 (0.7, 1.2) 0.55
Missing 18 (3%) 1.6 (0.9, 2.7) 0.08
Donor-recipient CMV match 0.006
−/− (reference) 118 (18%) 1.0
+/+ 325 (48%) 1.1 (0.9, 1.5) 0.38
+/− 69 (10%) 1.3 (0.9, 1.8) 0.20
−/+ 144 (21%) 1.2 (0.9, 1.7) 0.20
Missing 14 (2%) 3.1 (1.7, 5.6) <0.001
Karnofsky performance score 0.01
<90 (reference) 259 (39%) 1.0
90-100 399 (60%) 0.7 (0.6, 0.9) 0.004
Missing 12 (2%) 1.0 (0.5, 2.1) 0.97
NRM
GVHD prophylaxis 0.54
MTX-TAC (reference) 287 (43%) 1.0
MMF-CYSP 108 (16%) 1.3 (0.8, 2.1) 0.23
MTX-CYSP 212 (32%) 1.3 (0.9, 2.0) 0.19
MMF-TAC 63 (9%) 1.2 (0.7, 2.1) 0.51
Conditioning regimen / ATG 0.02
Bu+Flu+/−others (reference) 246 (37%) 1.0
ATG+/−Bu+/−Flu+/−others 131 (20%) 1.2 (0.7, 2.0) 0.47
Flu+Mel+/−others 188 (28%) 1.9 (1.3, 2.8) 0.002
TBI+/−Cy+/−Flu+/−others 105 (16%) 1.5 (0.9, 2.6) 0.10
Disease status 0.03
Early (reference) 390 (58%) 1.0
Advanced 146 (22%) 1.2 (0.8, 1.7) 0.32
Intermediate 116 (17%) 0.6 (0.4, 1.0) 0.07
Missing 18 (3%) 2.2 (1.0, 4.7) 0.04
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N (%) Est (95% CI) P-value
Donor-recipient sex match 0.002
M-M (reference) 219 (33%) 1.0
F-F 135 (20%) 0.9 (0.6, 1.5) 0.77
F-M 164 (24%) 1.8 (1.2, 2.7) 0.003
M-F 152 (23%) 1.0 (0.6, 1.6) 0.98
Sorror co-morbidity index 0.03
0-1 (reference) 134 (20%) 1.0
≥2 187 (28%) 2.3 (1.3, 4.2) 0.003
Missing 10 (1%) 2.4 (0.7, 8.3) 0.18
N/A Prior to 2007 339 (51%) 2.0 (1.2, 3.5) 0.01
Relapse
GVHD prophylaxis 0.22
MTX-TAC (reference) 287 (43%) 1.0
MMF-CYSP 108 (16%) 1.1 (0.7, 1.6) 0.70
MTX-CYSP 212 (32%) 0.7 (0.5, 1.0) 0.07
MMF-TAC 63 (9%) 0.9 (0.6, 1.5) 0.80
Conditioning regimen / ATG <0.001
Bu+Flu+/−others (reference) 246 (37%) 1.0
ATG+/−Bu+/−Flu+/−others 131 (20%) 1.1 (0.8, 1.5) 0.65
Flu+Mel+/−others 188 (28%) 0.4 (0.3, 0.6) <0.001
TBI+/−Cy+/−Flu+/−others 105 (16%) 0.9 (0.6, 1.3) 0.55
Disease 0.03
AML (reference) 393 (59%) 1.0
ALL 34 (5%) 0.9 (0.5, 1.8) 0.85
CML 59 (9%) 1.0 (0.6, 1.7) 0.96
MDS 184 (27%) 0.6 (0.5, 0.8) 0.003
Disease status <0.001
Early (reference) 390 (58%) 1.0
Advanced 146 (22%) 2.1 (1.5, 2.8) <0.001
Intermediate 116 (17%) 1.2 (0.8, 1.9) 0.28
Missing 18 (3%) 1.9 (0.9, 4.2) 0.11
Donor-recipient CMV match 0.02
−/− (reference) 118 (18%) 1.0
+/+ 325 (48%) 1.2 (0.9, 1.8) 0.23
+/− 69 (10%) 1.4 (0.9, 2.2) 0.15
−/+ 144 (21%) 1.3 (0.9, 1.9) 0.21
Missing 14 (2%) 3.3 (1.6, 6.7) <0.001
Sorror co-morbidity index 0.003
0-1 (reference) 134 (20%) 1.0 0.94
≥2 187 (28%) 1.0 (0.7, 1.4) 0.94
Missing 10 (1%) 0.4 (0.1, 1.4) 0.18
N/A Prior to 2007 339 (51%) 0.6 (0.4, 0.8) 0.001
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Abbreviations: N, number; Est, estimate; CI, confidence interval; GVHD, Graft-versus-Host Disease; MTX, methotrexate; TAC, tacrolimus; MMF, 
mycophenolate mofetil; CYSP, cyclosporine; ATG, anti-thymocyte globulin; Bu, busulfan; Flu, fludarabine; TBI, total body irradiation; Cy, 
cyclophosphamide; Mel, melphalan; CMV, cytomegalovirus; M, male; F, female; OS, overall survival; AML, acute myeloid leukemia; ALL, acute 
lymphoblastic leukemia; MDS, myelodysplastic syndrome; DFS, disease-free survival; NRM, non-relapse mortality; N/A, not available; RIC, 
reduced intensity conditioning; alloHCT, allogeneic hematopoietic cell transplantation













Chhabra et al. Page 31
Table 3B.
Multivariate analyses in unrelated donor RIC alloHCT
N (%) Est (95% CI) P-value
Grade II-IV aGVHD
GVHD prophylaxis <0.001
MTX-TAC (reference) 429 (49%) 1.0
MMF-CYSP 152 (17%) 1.8 (1.3, 2.4) <0.001
MTX-CYSP 71 (8%) 0.8 (0.5, 1.2) 0.29
MMF-TAC 216 (25%) 1.3 (1.0, 1.7) 0.03
Conditioning regimen / ATG 0.002
Bu+Flu+/−others (reference) 173 (20%) 1.0
ATG+/−Bu+/−Flu+/−others 414 (48%) 1.1 (0.8, 1.4) 0.61
Flu+Mel+/−others 147 (17%) 1.7 (1.3, 2.4) <0.001
TBI+/−Cy+/−Flu+/−others 134 (15%) 1.2 (0.8, 1.7) 0.37
Disease status 0.01
Early (reference) 512 (59%) 1.0
Advanced 206 (24%) 1.1 (0.9, 1.5) 0.25
Intermediate 127 (15%) 0.7 (0.5, 1.0) 0.03
Missing 23 (3%) 1.6 (0.9, 2.7) 0.08
Donor type
7/8-matched URD (reference) 172 (20%) 1.0




MTX-TAC (reference) 428 (49%) 1.0
MMF-CYSP 152 (18%) 1.9 (1.2, 3.1) 0.006
MTX-CYSP 71 (8%) 0.8 (0.4, 1.6) 0.53
MMF-TAC 214 (257%) 1.5 (1.0, 2.3) 0.03
Conditioning regimen / ATG <0.001
Bu+Flu+/−others (reference) 173 (20%) 1.0
ATG+/−Bu+/−Flu+/−others 412 (48%) 1.1 (0.7, 1.7) 0.78
Flu+Mel+/−others 146 (17%) 2.7 (1.6, 4.4) <0.001
TBI+/−Cy+/−Flu+/−others 134 (15%) 0.9 (0.5, 1.6) 0.66
Disease 0.02
AML (reference) 495 (57%) 1.0
ALL 39 (4%) 0.4 (0.1, 1.2) 0.10
CML 48 (5%) 2.1 (1.1, 4.0) 0.03
MDS 283 (33%) 1.4 (1.0, 2.0) 0.08
Disease status 0.04
Early (reference) 511 (59%) 1.0
Advanced 204 (24%) 1.2 (0.8, 1.7) 0.46
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N (%) Est (95% CI) P-value
Intermediate 127 (15%) 0.7 (0.4, 1.3) 0.25
Missing 23 (3%) 2.3 (1.2, 4.5) 0.01
Donor type
7/8-matched URD (reference) 172 (20%) 1.0




MTX-TAC (reference) 428 (49%) 1.0
MMF-CYSP 152 (17%) 1.3 (0.9, 1.7) 0.10
MTX-CYSP 70 (8%) 1.0 (0.7, 1.5) 0.96
MMF-TAC 217 (25%) 1.2 (0.9, 1.5) 0.18
Conditioning regimen / ATG <0.001
Bu+Flu+/−others (reference) 174 (20%) 1.0
ATG+/−Bu+/−Flu+/−others 413 (48%) 0.7 (0.6, 1.0.) 0.03
Flu+Mel+/−others 146 (17%) 1.4 (1.0, 1.9) 0.03
TBI+/−Cy+/−Flu+/−others 134 (15%) 1.4 (1.0, 2.0) 0.04
Year of transplant 0.03
2000-2004 (reference) 80 (9%) 1.0
2005-2008 366 (42%) 0.7 (0.5, 1.0) 0.03
2009-2013 421 (49%) 0.6 (0.4, 0.9) 0.007
OS
GVHD prophylaxis 0.82
MTX-TAC (reference) 432 (49%) 1.0
MMF-CYSP 153 (17%) 1.0 (0.8, 1.2) 0.97
MTX-CYSP 71 (8%) 1.1 (0.8, 1.5) 0.49
MMF-TAC 218 (25%) 1.1 (0.9, 1.3) 0.47
Age at transplant, years 0.008
18-29 (reference) 38 (4%) 1.0
30-39 54 (6%) 0.6 (0.3, 1.0) 0.03
40-49 80 (9%) 0.8 (0.5, 1.3) 0.37
50-64 444 (51%) 0.9 (0.6, 1.4) 0.67
65+ 258 (29%) 1.1 (0.7, 1.7) 0.55
Disease status 0.004
Early (reference) 515 (59%) 1.0
Advanced 208 (24%) 1.2 (1.0, 1.5) 0.02
Intermediate 127 (14%) 1.0 (0.8, 1.3) 0.82
Missing 24 (3%) 2.0 (1.3, 3.1) 0.002
Donor type
7/8-matched URD (reference) 172 (20%) 1.0
8/8-matched URD 702 (80%) 0.7 (0.6, 0.8) <0.001
Karnofsky performance score 0.002
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N (%) Est (95% CI) P-value
<90 (reference) 372 (43%) 1.0
90-100 475 (54%) 0.8 (0.6, 0.9) 0.001
Missing 27 (3%) 1.1 (0.7, 1.6) 0.71
Sorror co-morbidity index 0.05
0-1 (reference) 191 (22%) 1.0
≥2 315 (36%) 1.1 (0.9, 1.4) 0.43
Missing 20 (2%) 0.5 (0.3, 1.1) 0.09
N/A Prior to 2007 348 (40%) 1.2 (1.0, 1.5) 0.08
DFS
GVHD prophylaxis 0.68
MTX-TAC (reference) 423 (49%) 1.0
MMF-CYSP 153 (18%) 0.9 (0.7, 1.1) 0.28
MTX-CYSP 67 (8%) 1.0 (0.7, 1.4) 0.94
MMF-TAC 216 (25%) 1.0 (0.8, 1.2) 0.82
Age at transplant, years 0.04
18-29 (reference) 38 (4%) 1.0
30-39 52 (6%) 0.5 (0.3, 0.9) 0.02
40-49 78 (9%) 0.8 (0.5, 1.2) 0.24
50-64 439 (51%) 0.9 (0.6, 1.3) 0.59
65+ 252 (29%) 1.0 (0.6, 1.4) 0.88
Disease status 0.003
Early (reference) 511 (59%) 1.0
Advanced 204 (24%) 1.4 (1.1, 1.6) <0.001
Intermediate 121 (14%) 1.1 (0.9, 1.4) 0.46
Missing 23 (3%) 1.7 (1.0, 2.6) 0.03
Donor type
7/8-matched URD (reference) 170 (20%) 1.0
8/8-matched URD 689 (80%) 0.8 (0.6, 0.9) 0.006
Karnofsky performance score 0.005
<90 (reference) 361 (42%) 1.0
90-100 471 (55%) 0.8 (0.7, 0.9) 0.002




MTX-TAC (reference) 423 (49%) 1.0
MMF-CYSP 153 (18%) 1.4 (1.0, 1.9) 0.06
MTX-CYSP 67 (8%) 1.3 (0.8, 2.0) 0.26
MMF-TAC 216 (25%) 1.5 (1.1, 2.0) 0.008
Age at transplant, years 0.003
18-29 (reference) 38 (4%) 1.0
30-39 52 (6%) 0.6 (0.3, 1.3) 0.20
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N (%) Est (95% CI) P-value
40-49 78 (9%) 0.8 (0.4, 1.7) 0.60
50-64 439 (51%) 1.1 (0.6, 2.2) 0.69
65+ 252 (29%) 1.5 (0.8, 3.0) 0.20
Conditioning regimen / ATG 0.008
Bu+Flu+/−others (reference) 172 (20%) 1.0
ATG+/−Bu+/−Flu+/−others 410 (48%) 0.9 (0.6, 1.2) 0.43
Flu+Mel+/−others 143 (17%) 1.4 (1.0, 2.1) 0.05
TBI+/−Cy+/−Flu+/−others 134 (16%) 0.8 (0.5, 1.2) 0.35
Disease status 0.02
Early (reference) 511 (59%) 1.0
Advanced 204 (24%) 0.9 (0.7, 1.2) 0.68
Intermediate 121 (14%) 0.8 (0.6, 1.2) 0.34
Missing 23 (3%) 2.2 (1.3, 3.9) 0.006
Donor type <0.001
7/8-matched URD (reference) 170 (20%) 1.0
8/8-matched URD 689 (80%) 0.5 (0.4, 0.7) <0.001
Donor-recipient CMV match 0.04
−/− (reference) 215 (25%) 1.0
+/+ 201 (23%) 1.2 (0.8, 1.7) 0.30
+/− 80 (9%) 1.7 (1.1, 2.6) 0.01
−/+ 340 (40%) 1.3 (1.0, 1.8) 0.05
Missing 23 (3%) 2.2 (1.1, 4.2) 0.02
Karnofsky performance score 0.007
<90 (reference) 361 (42%) 1.0
90-100 471 (55%) 0.7 (0.5, 0.9) 0.002
Missing 27 (3%) 0.9 (0.5, 1.7) 0.82
Relapse
GVHD prophylaxis 0.006
MTX-TAC (reference) 423 (49%) 1.0
MMF-CYSP 153 (18%) 0.5 (0.4, 0.7) <0.001
MTX-CYSP 67 (8%) 0.8 (0.5, 1.2) 0.35
MMF-TAC 216 (25%) 0.7 (0.5, 1.0) 0.03
Conditioning regimen / ATG 0.003
Bu+Flu+/−others (reference) 172 (20%) 1.0
ATG+/−Bu+/−Flu+/−others 410 (48%) 0.8 (0.6, 1.1) 0.26
Flu+Mel+/−others 143 (17%) 0.5 (0.3, 0.7) <0.001
TBI+/−Cy+/−Flu+/−others 134 (16%) 1.0 (0.7, 1.5) 0.99
Disease 0.006
AML (reference) 492 (57%) 1.0
ALL 37 (4%) 1.1 (0.7, 1.9) 0.66
CML 48 (6%) 0.6 (0.3, 1.1) 0.09
MDS 282 (33%) 0.6 (0.5, 0.9) 0.002
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N (%) Est (95% CI) P-value
Disease status <0.001
Early (reference) 511 (59%) 1.0
Advanced 204 (24%) 1.8 (1.4, 2.3) <0.001
Intermediate 121 (14%) 1.2 (0.9, 1.7) 0.17
Missing 23 (3%) 1.2 (0.5, 2.8) 0.64
Sex 0.03
Male (reference) 487 (57%) 1.0
Female 372 (43%) 1.3 (1.0, 1.6) 0.03
Abbreviations: N, number; Est, estimate; CI, confidence interval; GVHD, Graft-versus-Host Disease; MTX, methotrexate; TAC, tacrolimus; MMF, 
mycophenolate mofetil; CYSP, cyclosporine; ATG, anti-thymocyte globulin; Bu, busulfan; Flu, fludarabine; TBI, total body irradiation; Cy, 
cyclophosphamide; Mel, melphalan; CMV, cytomegalovirus; M, male; F, female; OS, overall survival; AML, acute myeloid leukemia; ALL, acute 
lymphoblastic leukemia; MDS, myelodysplastic syndrome; DFS, disease-free survival; NRM, non-relapse mortality; N/A, not available; RIC, 
reduced intensity conditioning; alloHCT, allogeneic hematopoietic cell transplantation
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